Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 28.07.2021.

#biotech
#COVAX
#drug
#biopharma
#lifesciences
#COVID19
#mecialnews
#Environment
#Agriculture
#GoodDayBIO

Companies And Industries

@Biotechnology shared
On Jul 26, 2021
Clinical Catch-Up: July 19-23 https://t.co/GKGqbcXKcM https://t.co/0N9TXzodvp
Open
Clinical Catch-Up: July 19-23

Clinical Catch-Up: July 19-23

It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.

@biospace shared
On Jul 23, 2021
Create value & success will follow, @AnimaBiotech CEO Yochi Slonim says https://t.co/8qpxk7xSfJ
Open
Create Value & Success Will Follow, Anima Biotech CEO Yochi Slonim Says

Create Value & Success Will Follow, Anima Biotech CEO Yochi Slonim Says

“When big pharma collaborates with biopharma companies, the main risk isn’t the technology, but the commitment of the partner,” according to serial entrepreneur Yochi Slonim, CEO of Anima ...

@biospace shared
On Jul 27, 2021
Biotech companies announce big drug wins with @US_FDA #biotech #drug https://t.co/ZZsfvNigRO
Open
Biotech Companies Announce Big Drug Wins with FDA

Biotech Companies Announce Big Drug Wins with FDA

Several biotech and biopharmaceutical companies have announced new wins with the FDA, ranging from cancer treatment candidates to investigational agents for opioid use disorder.

@biospace shared
On Jul 26, 2021
@PKILifeScience Inc. life science growth with massive $5.25B acquisition #lifesciences #biopharma https://t.co/WfYTusL5yS
Open
PerkinElmer Continues Rapid Life Science Growth with Massive $5.25B Acquisition

PerkinElmer Continues Rapid Life Science Growth with Massive $5.25B Acquisition

It's been a long season of acquisitions for PerkinElmer. Now in its largest purchase ever, the company is buying biomedical research tool company BioLegend. 

@IAmBiotech shared
On Jul 22, 2021
#GoodDayBIO: Details on the #COVAX Marketplace, a platform designed to support global supply chains for production of #COVID19 vaccines. Meet BIO’s new VP for #Agriculture and #Environment, Sarah Gallo. https://t.co/gIwnSPBtoQ
Open
Good Day BIO: COVAX Marketplace will boost global vaccine production

Good Day BIO: COVAX Marketplace will boost global vaccine production

Lots of newness today: the new COVAX Marketplace, BIO’s new VP for Agriculture and Environment, and more news from Washington. (888 words, 4 minutes, 26 seconds)

@GENbio shared
On Jul 26, 2021
IPO Raises $304M for Caribou, Developer of Gene-Edited Cell Therapies @CaribouBiohas launched an upsized initial public offering that raised $304 million in gross proceeds—about $50 million more than projected just a day earlier. Learn more: https://t.co/Smp6icoRNQ https://t.co/QGVkKPti0H
Open
IPO Raises $304M for Caribou, Developer of Gene-Edited Cell Therapies

IPO Raises $304M for Caribou, Developer of Gene-Edited Cell Therapies

Caribou Biosciences, the developer of gene-edited cell therapies co-founded by Nobel laureate Jennifer Doudna, PhD, has launched an upsized initial public offering that raised $304 million ...

@biospace shared
On Jul 22, 2021
Fel d 1 protein sparking curiosity that could change the cat #medicalstudy #research https://t.co/2wPHPEKV6d
Open
Fel d 1 Protein Sparking Curiosity that Could Change the Cat

Fel d 1 Protein Sparking Curiosity that Could Change the Cat

Companies such as Indoor Biotechnologies in Virginia are leveraging cutting-edge scientific techniques to not only reduce the amount of the protein expressed but completely knock it out. 

@GENbio shared
On Jul 27, 2021
.@PerkinElmer said today it agreed to acquire @BioLegend a provider of life science antibodies and reagents, for approximately $5.25 billion in cash and stock, in a deal designed to position PerkinElmer as a leading #precisionmedicine company. Learn more: https://t.co/8lGNiE0g3N https://t.co/jIhtzrpdGZ
Open
PerkinElmer to Acquire Antibody, Reagent Maker BioLegend for $5.25B

PerkinElmer to Acquire Antibody, Reagent Maker BioLegend for $5.25B

PerkinElmer said today it agreed to acquire BioLegend, a provider of life science antibodies and reagents, for approximately $5.25 billion in cash and stock, in a deal designed to position ...